Danon disease as a cause of autophagic vacuolar myopathy

Congenital Heart Disease

Volumn 2, Issue 6, 2007, Pages 404-409

  Yang, Zhao ^a,b   Vatta, Matteo ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

AVM; Danon Disease; HCM; Hypertrophic Cardiomyopathy; LAMP2; Skeletal Myopathy

Indexed keywords

LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2;

AUTOPHAGIC VACUOLAR MYOPATHY; BARTH SYNDROME; CARDIOMYOPATHY; CELL FUNCTION; CELL STRUCTURE; CLINICAL FEATURE; DANON DISEASE; DIFFERENTIAL DIAGNOSIS; GENE MUTATION; GENETIC HETEROGENEITY; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; INHERITANCE; LYSOSOME; MENTAL DEFICIENCY; MOLECULAR GENETICS; MUSCLE BIOPSY; MUTATIONAL ANALYSIS; MYOPATHY; NEUROLOGIC EXAMINATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RETINOPATHY; REVIEW;

ANIMALS; AUTOPHAGY; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; GENETIC HETEROGENEITY; GLYCOGEN STORAGE DISEASE TYPE IIB; HUMANS; INHERITANCE PATTERNS; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; LYSOSOMES; MENTAL RETARDATION; MUSCULAR DISEASES;

EID: 36348984527     PISSN: 1747079X     EISSN: 17470803     Source Type: Journal    
DOI: 10.1111/j.1747-0803.2007.00132.x     Document Type: Review

References (54)

1. Danon MJ, Oh SJ, DiMauro S, et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology. 1981;31:51-57.
2. Ausems MG, Lochman P, van Diggelen OP, et al. A diagnostic protocol for adult-onset glycogen storage disease type II. Neurology. 1999;52:851-853.
3. Sugie K, Noguchi S, Kozuka Y, et al. Autophagic vacuoles with sarcolemmal features delineate Danon disease and related myopathies. J Neuropathol Exp Neurol. 2005;64:513-522.
4. Nishino I. Autophagic vacuolar myopathies. Curr Neurol Neurosci Rep. 2003;3:64-69.
5. Nishino I. Autophagic vacuolar myopathy. Semin Pediatr Neurol. 2006;13:90-95.
6. Froissart R, Maire I. Danon disease. Orphanet Encyclopedia January 2002; Available at: http://www.orpha.net/data/patho/GB/uk-Danon.pdf. Accessed August 15, 2007.
7. Sugie K, Yamamoto A, Murayama K, et al. Clinicopathological features of genetically confirmed Danon disease. Neurology. 2002;58:1773-1778.
8. Bergia B, Sybers HD, Butler IJ. Familial lethal cardiomyopathy with mental retardation and scapuloperoneal muscular dystrophy. J Neurol Neurosurg Psychiatry. 1986;49:1423-1426.
9. Dworzak F, Casazza F, Mora M, et al. Lysosomal glycogen storage with normal acid maltase: A familial study with successful heart transplant. Neuromuscul Disord. 1994;4:243-247.
10. Lobrinus JA, Schorderet DF, et al. Morphological, clinical and genetic aspects in a family with a novel LAMP-2 gene mutation (Danon disease). Neuromuscul Disord. 2005;15:293-298.
11. Balmer C, Ballhausen D, Bosshard NU, et al. Familial X-linked cardiomyopathy (Danon disease): Diagnostic confirmation by mutation analysis of the LAMP2 gene. Eur J Pediatr. 2005;164:509-514.
12. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med. 2005;352:362-372.
13. Yang Z, McMahon CJ, Smith LR, et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation. 2005;112:1612-1617.
14. Fanin M, Nascimbeni AC, Fulizio L, Spinazzi M, Melacini P, Angelini C. Generalized lysosome-associated membrane protein-2 defect explains multisystem clinical involvement and allows leukocyte diagnostic screening in Danon disease. Am J Pathol. 2006;168:1309-1320.
15. Riggs JE, Schochet SS Jr, Gutmann L, Shanske S, Neal WA, DiMauro S. Lysosomal glycogen storage disease without acid maltase deficiency. Neurology. 1983;33:873-877.
16. Tripathy D, Coleman RA, Vidaillet HJ Jr, Steenbergen C, Hirschhorn K, Packer DL. Complete heart block with myocardial membrane-bound glycogen and normal peripheral alpha-glucosidase activity. Ann Intern Med. 1988;109:985-987.
17. Laforet P, Charron P, Maisonobe T, et al. Charcot-Marie-Tooth features and maculopathy in a patient with Danon disease. Neurology. 2004;63:1535.
18. Murakami N, Goto Y, Itoh M, Katsumi Y, Wada T, Ozawa E, Nonaka I. Sarcolemmal indentation in cardiomyopathy with mental retardation and vacuolar myopathy. Neuromuscul Disord. 1995;5:149-155.
19. Bertini E, Donati MA, Broda P, et al. Phenotypic heterogeneity in two unrelated Danon patients associated with the same LAMP-2 gene mutation. Neuropediatrics. 2005;36:309-313.
20. Charron P, Villard E, Sebillon P, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: A systematic survey. Heart. 2004;90:842-846.
21. Lacoste-Collin L, Garcia V, Uro-Coste E, et al. Danon's disease (X-linked vacuolar cardiomyopathy and myopathy): A case with a novel Lamp-2 gene mutation. Neuromuscul Disord. 2002;12:882-885.
22. Prall FR, Drack A, Taylor M, et al. Ophthalmic manifestations of Danon disease. Ophthalmology. 2006;113:1010-1013.
23. Schorderet DF, Cottet S, Lobrinus JA, Borruat FX, Balmer A, Munier FL. Retinopathy in Danon disease. Arch Ophthalmol. 2007;125:231-236.
24. Holton JL, Beesley C, Jackson M, et al. Autophagic vacuolar myopathy in twin girls. Neuropathol Appl Neurobiol. 2006;32:253-259.
25. Byrne E, Dennett X, Crotty B, et al. Dominantly inherited cardioskeletal myopathy with lysosomal glycogen storage and normal acid maltase levels. Brain. 1986;109:523-536.
26. Sugie K, Koori T, Yamamoto A, et al. Characterization of Danon disease in a male patient and his affected mother. Neuromuscul Disord. 2003;13:708-711.
27. Kornfeld S, Mellman I. The biogenesis of lysosomes. Annu Rev Cell Biol. 1989;5:483-525.
28. Eskelinen EL, Tanaka Y, Saftig P. At the acidic edge: Emerging functions for lysosomal membrane proteins. Trends Cell Biol. 2003;13:137-145.
29. Bosch E, Horwitz J, Bok D. Phagocytosis of outer segments by retinal pigment epithelium: Phagosome-lysosome interaction. J Histochem Cytochem. 1993;41:253-263.
30. Mattei MG, Matterson J, Chen JW, Williams MA, Fukuda M. Two human lysosomal membrane glycoproteins, h-lamp-1 and h-lamp-2, are encoded by genes localized to chromosome 13q34 and chromosome Xq24-25, respectively. J Biol Chem. 1990;265:7548-7551.
31. Schleutker J, Haataja L, Renlund M, et al. Confirmation of the chromosomal localization of human lamp genes and their exclusion as candidate genes for Salla disease. Hum Genet. 1991;88:95-97.
32. Blair HJ, Ho M, Monaco AP, Fisher S, Craig IW, Boyd Y. High-resolution comparative mapping of the proximal region of the mouse X chromosome. Genomics. 1995;28:305-310.
33. Eskelinen EL, Cuervo AM, Taylor MR, et al. Unifying nomenclature for the isoforms of the lysosomal membrane protein LAMP-2. Traffic. 2005;6:1058-1061.
34. Konecki DS, Foetisch K, Zimmer KP, Schlotter M, Lichter-Konecki U. An alternatively spliced form of the human lysosome-associated membrane protein-2 gene is expressed in a tissue-specific manner. Biochem Biophys Res Commun. 1995;215:757-767.
35. Konecki DS, Foetisch K, Schlotter M, Lichter-Konecki U. Complete cDNA sequence of human lysosome-associated membrane protein-2. Biochem Biophys Res Commun. 1994;205:1-5.
36. Fukuda M. Biogenesis of the lysosomal membrane. Subcell Biochem. 1994;22:199-230.
37. Tanaka Y, Guhde G, Suter A, et al. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature. 2000;406:902-906.
38. Huynh KK, Eskelinen EL, Scott CC, Malevanets A, Saftig P, Grinstein S. LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J. 2007;26:313-324.
39. Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. Science. 1996;273:501-503.
40. Cuervo AM, Dice JF. Unique properties of lamp2a compared to other lamp2 isoforms. J Cell Sci. 2000;113 (pt 24):4441-4450.
41. Nishino I, Fu J, Tanji K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature. 2000;406:906-910.
42. Horvath J, Ketelsen UP, Geibel-Zehender A, et al. Identification of a novel LAMP2 mutation responsible for X-chromosomal dominant Danon disease. Neuropediatrics. 2003;34:270-273.
43. Stypmann J, Janssen PM, Prestle J, et al. LAMP-2 deficient mice show depressed cardiac contractile function without significant changes in calcium handling. Basic Res Cardiol. 2006;101:281-291.
44. Eskelinen EL, Illert AL, Tanaka Y, et al. Role of LAMP-2 in lysosome biogenesis and autophagy. Mol Biol Cell. 2002;13:3355-3368.
45. Saviranta P, Lindlof M, Lehesjoki AE, et al. Linkage studies in a new X-linked myopathy, suggesting exclusion of DMD locus and tentative assignment to distal Xq. Am J Hum Genet. 1988;42:84-88.
46. Kalimo H, Savontaus ML, Lang H, et al. X-linked myopathy with excessive autophagy: A new hereditary muscle disease. Ann Neurol. 1988;23:258-265.
47. Villard L, des Portes V, Levy N, et al. Linkage of X-linked myopathy with excessive autophagy (XMEA) to Xq28. Eur J Hum Genet. 2000;8:125-129.
48. Minassian BA, Aiyar R, Alic S, et al. Narrowing in on the causative defect of an intriguing X-linked myopathy with excessive autophagy. Neurology. 2002;59:596-601.
49. Yan C, Tanaka M, Sugie K, et al. A new congenital form of X-linked autophagic vacuolar myopathy. Neurology. 2005;65:1132-1134.
50. Morisawa Y, Fujieda M, Murakami N, et al. Lysosomal glycogen storage disease with normal acid maltase with early fatal outcome. J Neurol Sci. 1998;160:175-179.
51. Verloes A, Massin M, Lombet J, et al. Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency. Delineation of a neonatal form. Am J Med Genet. 1997;72:135-142.
52. Yamamoto A, Morisawa Y, Verloes A, et al. Infantile autophagic vacuolar myopathy is distinct from Danon disease. Neurology. 2001;57:903-905.
53. Kaneda D, Sugie K, Yamamoto A, et al. A novel form of autophagic vacuolar myopathy with late-onset and multiorgan involvement. Neurology. 2003;61:128-131.
54. Towbin JA, Hejtmancik JF, Brink P, et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation. 1993;87:1854-1865.